“…The purpose of THS 2.2 is to deliver a nicotine-containing aerosol from tobacco, with significantly reduced levels of the toxicants found in CS. When compared with CS, THS 2.2 aerosol contains significantly lower levels of toxicants, including harmful and potentially harmful constituents (HPHCs) ( Mallock et al , 2018 ; Schaller et al , 2016a , b ), and free radicals ( Shein and Jeschke, 2019 ) and no carbon-based solid particles ( Pratte et al , 2017 , 2018 ). A series of studies have demonstrated that, relative to CS, THS 2.2 aerosol has significantly reduced cytotoxicity, reduced mutagenic potency in the mouse lymphoma assay, and no mutagenic effect in the Ames assay ( Schaller et al , 2016a ; Thorne et al , 2018 ); it also has a reduced biological impact on human 3D organotypic bronchial, small airway, and oral epithelial cultures ( Gonzalez-Suarez et al , 2016 ; Iskandar et al , 2017a , b ; Zanetti et al , 2016 ) and significantly reduced systemic toxicity, lung inflammation, respiratory tract alterations, and disease risk in rodent laboratory models of chronic obstructive pulmonary disease (COPD) and atherosclerosis ( Oviedo et al , 2016 ; Phillips et al , 2016 , 2019a ; Wong et al , 2016 ).…”